Neox Biotech

NeoX Biotech (星亢原) is a Beijing-based biotechnology company working at the intersection of AI and pharmaceutical research, an area 5Y Capital internally labels "ITBT." The firm was among the earliest Chinese AI-drug-discovery bets for 5Y Capital, which also backed XtalPi, xbiome, and Galixir in the same wave . In March 2021, neoX closed a $30 million Series A led jointly by Sky9 Capital and 5Y Capital, with follow-on from BAI, Vertex Ventures, and continued support from existing investors Yuanjing Capital and Sequoia China . It raised an A+ round later that year , and by 2022 its co-founder and CEO Chen Hang was being featured alongside other 5Y portfolio founders at industry roundtables on ITBT commercialization . The company was named to CVCA's 2021 top-10 biopharma investment cases . Elsewhere's corpus does not contain more recent operational or clinical updates.